Barclays PLC Increases Holdings in Five Prime Therapeutics Inc (FPRX)

Barclays PLC lifted its stake in Five Prime Therapeutics Inc (NASDAQ:FPRX) by 261.8% in the 1st quarter, HoldingsChannel reports. The firm owned 25,447 shares of the biotechnology company’s stock after acquiring an additional 18,414 shares during the period. Barclays PLC’s holdings in Five Prime Therapeutics were worth $437,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its stake in shares of Five Prime Therapeutics by 17.8% in the 1st quarter. The Manufacturers Life Insurance Company now owns 25,032 shares of the biotechnology company’s stock worth $430,000 after purchasing an additional 3,782 shares in the last quarter. A.R.T. Advisors LLC increased its stake in shares of Five Prime Therapeutics by 4.3% in the 1st quarter. A.R.T. Advisors LLC now owns 158,769 shares of the biotechnology company’s stock worth $2,727,000 after purchasing an additional 6,500 shares in the last quarter. Rock Springs Capital Management LP increased its stake in shares of Five Prime Therapeutics by 37.8% in the 1st quarter. Rock Springs Capital Management LP now owns 585,500 shares of the biotechnology company’s stock worth $10,059,000 after purchasing an additional 160,500 shares in the last quarter. UBS Group AG increased its stake in shares of Five Prime Therapeutics by 773.8% in the 1st quarter. UBS Group AG now owns 98,653 shares of the biotechnology company’s stock worth $1,695,000 after purchasing an additional 87,363 shares in the last quarter. Finally, Platinum Investment Management Ltd. increased its stake in shares of Five Prime Therapeutics by 50.0% in the 1st quarter. Platinum Investment Management Ltd. now owns 94,200 shares of the biotechnology company’s stock worth $1,618,000 after purchasing an additional 31,400 shares in the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

A number of equities research analysts have issued reports on the company. Raymond James assumed coverage on Five Prime Therapeutics in a research note on Thursday, June 28th. They issued a “market perform” rating for the company. BidaskClub upgraded Five Prime Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, June 27th. Zacks Investment Research lowered Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, June 27th. JPMorgan Chase & Co. assumed coverage on Five Prime Therapeutics in a research note on Friday, June 15th. They issued a “neutral” rating and a $19.00 price target for the company. Finally, ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 2nd. One analyst has rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $33.00.

Shares of FPRX stock opened at $16.11 on Tuesday. Five Prime Therapeutics Inc has a 52-week low of $15.32 and a 52-week high of $48.87. The firm has a market capitalization of $556.66 million, a price-to-earnings ratio of -2.99 and a beta of 3.43.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.08). Five Prime Therapeutics had a negative return on equity of 44.36% and a negative net margin of 221.74%. The business had revenue of $32.49 million during the quarter, compared to analysts’ expectations of $37.50 million. equities analysts expect that Five Prime Therapeutics Inc will post -4.67 earnings per share for the current fiscal year.

Five Prime Therapeutics Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics Inc (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply